News
SLDB
8.98
+5.15%
0.44
Solid Bioscience: Other definitive proxy statementsOpen document
Press release · 1d ago
Edgewise gets EU orphan drug status for muscular dystrophy drug
Edgewise gets EU orphan drug status for muscular dystrophy drug. Edgewise Therapeutics has received orphan drug designation from EU regulators for its drug candidate sevasemten. The drug candidate is in the treatment of Becker muscular dy Strophy and Duchenne muscular dystrophy.
Seeking Alpha · 5d ago
Weekly Report: what happened at SLDB last week (0415-0419)?
Weekly Report · 6d ago
Weekly Report: what happened at SLDB last week (0408-0412)?
Weekly Report · 04/15 09:09
Private equity firms invested in Solid Biosciences Inc. (NASDAQ:SLDB) copped the brunt of last week's US$64m market cap decline
Solid Biosciences Inc. (NASDAQ:SLDB) has a total of 50% ownership of the company. Private equity firms own 37% of Solid B biosciences. The company is owned by 5 shareholders, with a majority of the stock in private equity firms. The top 5 shareholders of the firm are believed to have a significant influence over the business. We look at the company's ownership of shares to see how the company operates.
Simply Wall St · 04/11 11:59
Buy Solid Biosciences: Unpacking Its Main Value Driver
Seeking Alpha · 04/10 23:32
Weekly Report: what happened at SLDB last week (0401-0405)?
Weekly Report · 04/08 09:10
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Solid Biosciences Inc. Is a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases. The company announced the grant of inducement awards to two newly hired employees. The grants were made pursuant to the Company's 2024 Inducement Stock Incentive Plan.
Barchart · 04/03 15:05
Solid Biosciences (SLDB) Falls Despite FDA Rare Tag for DMD Drug
NASDAQ · 04/02 14:35
Solid Biosciences gets FDA rare pediatric disease status for DMD therapy
Healthcare Solid Biosciences gets FDA rare pediatric disease status for DMD therapy. SGT-003 for the treatment of Duchenne muscular dystrophy. The company expects the first patient in a Phase 1/2 study for the therapy to be dosed in Q2.
Seeking Alpha · 04/01 14:17
Solid Biosciences: FDA Grants Rare Pediatric Disease Designation For SGT-003
NASDAQ · 04/01 12:40
Solid Biosciences Gets FDA Rare-Pediatric Designation for SGT-003 in Duchenne
Solid Biosciences has won U.S. Food and Drug Administration rare-pediatric-disease designation for its SGT-003 gene-therapy candidate for Duchenne muscular dystrophy. The company says it expects to begin dosing patients in the study in the second quarter.
Dow Jones · 04/01 11:59
Solid Biosciences Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003
Benzinga · 04/01 11:48
SOLID BIOSCIENCES INC - ANTICIPATE PROVIDING AN INITIAL SAFETY UPDATE FOR FIRST THREE TO FOUR PATIENTS ENROLLED IN INSPIRE DUCHENNE TRIAL IN MID-2024
Reuters · 04/01 11:45
Weekly Report: what happened at SLDB last week (0325-0329)?
Weekly Report · 04/01 09:10
William Blair starts Solid Biosciences at outperform
Healthcare William Blair starts Solid Biosciences at outperform rating. Firm cites its market opportunities in Duchenne muscular dystrophy, and rare cardiac diseases. William Blair set a fair value of $40 for the stock. The investment firm sees Solid as a ‘fast follower’ in DMD.
Seeking Alpha · 03/28 16:38
Solid Biosciences Price Target Announced at $40.00/Share by William Blair
Dow Jones · 03/28 14:52
Solid Biosciences Initiated at Outperform by William Blair
Dow Jones · 03/28 14:52
More
Webull provides a variety of real-time SLDB stock news. You can receive the latest news about Solid Bioscience through multiple platforms. This information may help you make smarter investment decisions.
About SLDB
Solid Biosciences Inc. is a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases. The Company is focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy, and additional assets for the treatment of fatal cardiac diseases. The Company also has two cardiac pipeline gene transfer programs, SGT-601 for TNNT2 DCM and SGT-701 for RBM20 DCM, that are both in early preclinical development. It also has a neuromuscular gene transfer program for the treatment of Friedreich's ataxia. In addition to its gene transfer candidates, the Company has development programs focusing on platform technologies, including novel capsid libraries and dual gene expression, a technology that allows it to package multiple transgenes into one capsid.